ArticleJournal of gastric cancer2022

Apatinib as a Third-Line Treatment for HER2-Positive Metastatic Gastric Cancer: A Multi-Center Single-Arm Cohort Study.

Xin Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.